Pravachol Articles
Atorvastatin Treatment IND Approved
13 March 1995
Bristol-Myers Squibb Has "Best Combo Of Businesses"
20 February 1995
Simvastatin Improves Survival; 4S Study
28 November 1994
Solid 3rd Qtr Growth For Large Pharma Cos
31 October 1994
Strong Gains By US Firms In 2nd Quarter
1 August 1994
MERCK/SANDOZ VIE FOR MARKET SHARE
27 June 1994
PRAVASTATIN REDUCES MI RISK
13 June 1994
CURRENCIES STILL A FACTOR IN US 1st QTR
2 May 1994
JAPANESE COs TOO DEPENDENT ON HOME MKT
11 April 1994
ISSUES RAISED AND TRIALS PRESENTED AT ACC
28 March 1994
PRICE WAR LOOMING FOR HYPOLIPEMICS
28 March 1994
JAPAN PHARMA MARKET IS LARGE, POOR PERFORMER
14 March 1994
PRAVASTATIN FINDING
28 February 1994
COST-CONTAINMENT, A BITTER PILL FOR INDUSTRY
21 February 1994
STRONG DOLLAR WEAKENS US 1993 RESULTS
31 January 1994
FDA YEAR-END APPROVALS FOR 1993
10 January 1994
PRIMARY PREVENTION WITH B-MS' PRAVASTATIN
8 November 1993
US 3rd QTR AFFECTED BY STRONG DOLLAR
1 November 1993
US PRESCRIBING TRENDS IN MARCH
28 June 1993
PRICE FLEXIBILITY AND THE DRUG INDUSTRY
12 April 1993
JOB CUTS AND EARNINGS WARNING FROM MERCK
5 April 1993
MERCK CLAIMS EFFICACY ADVANTAGE FOR STATINS
1 June 1992
STRONG INCREASES IN 1991 AT BRISTOL-MYERS SQUIBB
20 April 1992
MERCK AFFIRMS SAFETY of MEVACOR
9 March 1992
DECEMBER US APPROS REVIEWED
20 January 1992
SB JOINS MERCK TO MARKET ZOCOR
6 January 1992
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
